Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025\n\n\n\n TORONTO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“\n \n Quantum BioPharma\n \n ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced its licensee – Unbuzzd Wellness Inc. (the \"\n \n Company\n \n \" or \"\n \n Unbuzzd\n \n \"), the company behind unbuzzd™ — the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, as part of its Reg D 506 (c) offering and up to $5 million raise, the Company will host an Investor Webinar on Wednesday, October 1, 2025 at 430 pm EST (130 pm PST). The shareholders of Quantum BioPharma will not be diluted by this offering.\n \n\n During the webinar, Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David will discuss the current investment opportunity for its scientifically backed beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms. Investors will also learn about Company leadership, and their path to scale distribution and retail sales. A question-and-answer session will follow the presentation. To register, please click here\n \n link\n \n .\n \n\n CEO John Duffy commented, “We look forward to hosting potential investors for a discussion about how Unbuzzd is changing the way the world recovers from alcohol with our clinically proven wellness and recovery consumer product. We’ll also discuss the compelling opportunity for investors to be part of our success through our Regulation D 506(c) offering to raise up to US$5.0 million to support direct-to-consumer, distributor and retail expansion plans, and establish a path to a possible initial public offering.”\n \n\n A replay of the webinar will be available upon request by contacting\n \n [email protected]\n \n or 518-862-5993. To learn more about the Reg D 506(c) offering or begin yo...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B